An Antimicrobial Coating and a Cost-Effective Manufacturing Process to Apply it to Orthopaedic Implants, Reducing Surgical Site Infections by >50%

Accentus是一家总部位于英国的医疗技术中小企业，其核心项目团队包括Philip Agg（首席执行官）、James Shawcross（研发总监），Andrew Turner（首席科学家），大卫刘易斯（实验室经理）和Agnes Gardner手术部位感染（SSI）极大地降低了患者的生活质量，因为预期的治疗导致通常需要进一步住院和手术的并发症，伴随着成本和风险。这些后续治疗对医院来说也是一个巨大的成本负担，从初级程序中抽取资源。随着医院试图减少抗生素的使用，这可能会增加医院获得性感染的发生率，外科植入物表面的抗菌治疗越来越突出。然而，尽管钴铬合金材料在植入物中有着广泛的应用，但钴铬合金材料却没有这样的处理方法。Accentus正在开发一种用于钴铬合金骨科植入物的抗菌表面处理方法和一种具有成本效益的应用方法。这种安全有效的治疗方法将保留原始材料的基本特性，同时将SSI减少50%以上，使所有患者受益，尤其是那些需要保肢或翻修的患者。Accentus的方法是独一无二的，因为它建立在临床证明的技术基础上，并将其扩展到一种新材料。

Accentus is a UK-based medtech SME with a core project team of Philip Agg (CEO), James Shawcross (R&D Director), Andrew Turner (Principal Scientist), David Lewis (Laboratory Manager) and Agnes Gardner (Process Technician).Surgical site infections (SSIs) greatly diminish patient quality of life, as an intended treatment leads to complications that often require further hospitalisations and surgeries, with the attendant costs and risks. These follow-on treatments also represent a substantial cost burden to hospitals, drawing resources away from primary procedures. As hospitals try to reduce antibiotic use, which can increase the incidence of hospital-acquired infections, antimicrobial treatments on surgical implant surfaces are gaining prominence. However, no such treatments exist for cobalt-chromium materials, despite their common usage in implants.Accentus is developing an antimicrobial surface treatment for cobalt-chromium orthopaedic implants and a cost-effective method of application. This safe and effective treatment will retain the essential properties of the original material while reducing SSIs by \>50%, benefiting all patients but especially those needing limb salvage or revision. Accentus' approach is unique because it builds on a clinically proven technique and extends it to a new material.